

THERAPEUTIC DELIVERY SOLUTIONS



Edited By Chung Chow Chan, Kwok Chow, Bill McKay & Michelle Fung

THERAPEUTICS

Medical Devices

Pharmaceuticals

Cell Therapies



WILEY

CONTENTS

[Cover](#)

[Title page](#)

[Copyright page](#)

[Preface](#)

[Contributors](#)

[Acknowledgment](#)

[Section 1: Requirements and Issues encountered in Regulatory Submissions in the Pharmaceutical, Cell Therapy and Medical Device Industries](#)

[1 Challenges to Quality and Regulatory Requirement in the United States—Drugs, Medical Device, and Cell Therapy](#)

[1.1 Overview of Regulatory Requirements for Pharmaceutical, Medical Device, and Cell Therapies](#)

[1.2 Regulatory Requirements and Challenges for Pharmaceutical, Medical Device, and Cell Therapies](#)

[1.3 Initiatives in the Pharmaceutical, Medical Device, and Cell Therapy Regulatory Requirements](#)

[1.4 Current Good Manufacturing Practice Requirements for Combination Products](#)

[1.5 Conclusion](#)

[References](#)

[Section 2: Traditional Pharmaceutical Drug Therapy Development](#)

[2 Development of Tablets](#)

[2.1 Introduction](#)

[2.2 Development Plan and Milestones in TPP](#)

[2.3 Clinical Target Profile](#)

[2.4 Drug Substance Characteristics in TPP](#)

[2.5 Drug Product Characteristics in TPP](#)

[2.6 Drug Substance and Drug Product Specifications in TPP](#)

[2.7 Product Composition in TPP](#)

[2.8 Product Manufacturing in TPP](#)

[2.9 Conclusion](#)

[References](#)

[3 Formulation of Poorly Soluble Drugs for Oral Administration](#)

[3.1 Introduction](#)

[3.2 Upfront Assessments](#)

[3.3 Particle Engineering of Drug Substance](#)

[3.4 Animal Formulations and Screening of Delivery Technologies](#)

[3.5 Parallel Technology Screening Program for Human Formulations](#)

[3.6 Animal Pharmacokinetic Studies and Clinical Formulation Development](#)

[3.7 Decision Tree for Commercially Viable Delivery Systems and Formulations](#)

[3.8 Conclusion](#)

[References](#)

[Section 3: Overview, Current Trends and Strategies of Special Medical Device Development](#)

[4 Overview of Drug Delivery Devices](#)

[4.1 Introduction](#)

[4.2 Trends and Drivers for Drug Delivery Devices](#)

[4.3 Regulation of Medical Devices](#)

[4.4 The Development of Drug/Device Combination Products](#)

[4.5 Common Therapeutic Routes of Administration that Require a Medical Device](#)

[4.6 Future Direction for Drug Delivery Devices](#)

[References](#)

[5 Local Delivery of Bone Growth Factors](#)

[5.1 Applications for Local Delivery of Bone Growth Factors](#)

[5.2 Types of Bone Growth Factors](#)

[5.3 Delivery Systems](#)

[5.4 Current Status of Bone Growth Factor-Containing Products](#)

[5.5 Future Research Areas](#)

[5.6 Conclusions](#)

[References](#)

[6 Delivery of Insulin:](#)

[6.1 Introduction](#)

[6.2 The Physiology of Insulin Delivery in the Normal Human](#)

[6.3 The Early Days](#)

[6.4 Better Syringes and, for the First Time, a Meter](#)

[6.5 The DCCT Study and Why Control Matters](#)

[6.6 Implantable Insulin Pumps: The Beginning of Continuous Insulin Delivery](#)

[6.7 External Insulin Pumps: The Early Days](#)

[6.8 What to Deliver?](#)

[6.9 How to Deliver the New Insulin: Pens and Pumps](#)

[6.10 The Future: Next 10 Years](#)

[6.11 Other Uses](#)

[6.12 Conclusions](#)

[References](#)

[Section 4: Advances and Innovations in Cellular and Stem Cell Therapeutic Delivery](#)

[7 Endocrine Therapeutic Delivery](#)

[7.1 Introduction](#)

[7.2 History](#)

[7.3 Indications](#)

[7.4 Human Pancreatic Islet Processing and Transplantation](#)

[7.5 Potential Complications of Islet Transplantation](#)

[7.6 Current Outcomes](#)

[7.7 Challenges and Areas of Ongoing Research](#)

[7.8 Conclusion](#)

[7.9 Current Status of Research](#)

[References](#)

[8 Cell-Based Biologic Therapy for the Treatment of Medical Diseases](#)

[8.1 Introduction](#)

[8.2 Engineered or Processed Human Cells as Treatment Modalities](#)

[8.3 Cell-Based Immunotherapy](#)

[8.4 Conclusion](#)

[References](#)

9 Development of Stem Cell Therapy for Medical Uses

9.1 Introduction

9.2 History of Stem Cell Development

9.3 Sources of Nonembryonic Stem Cells

9.4 Stem Cell Technology and Preparation

9.5 Regulatory Considerations and Product Testing

9.6 Application for Medical Practice

9.7 Conclusions and Outlook for the Future

References

Section 5: Analytical Support Needed For the Research and Development

10 Specification Setting and Stability Studies in the Development of Therapeutic Delivery Solution

10.1 Introduction

10.2 Specifications for Test Procedures and Acceptance Criteria for Drug Substances and Drug Products

10.3 Stability Testing for New Drug Substances and Drug Products

10.4 Initiation of Stability Studies

10.5 Photostability Testing of New Drug Substances and Drug Products

References

11 LC-MS for Pharmaceutical Analysis

11.1 Introduction

11.2 LC-MS Instrumentation

11.3 Examples of Qualitative and Quantitative Applications

11.4 Summary

References

12 Biorelevant Dissolution Testing

12.1 Background

12.2 Dissolution Apparatus

12.3 Media Used in Dissolution Testing

12.4 *In Vitro/In Vivo* Correlation (IVIVC)

12.5 Summary

References

13 ICH Quality Guidelines

13.1 Introduction

13.2 Global Harmonization Forums

13.3 ICH Process

13.4 Impact of ICH Guidelines

13.5 Conclusion

Further Reading

14 Out of Specification/Atypical RESULT Investigation

14.1 Background

14.2 Identifying and Assessing OOS Test Results— Phase I: Laboratory Investigation

14.3 Expanded Investigating OOS/Atypical Test Results

14.4 Concluding the Investigation

14.5 Corrective and Preventive Action

Appendix i

Appendix ii Suggested OOS Investigation Flowchart

Appendix iii Example of initial assessment form

Appendix iv Example of reanalysis plan form

[Appendix v Example of retest plan I form](#)
[Appendix vi Example of retest plan II form](#)
[Appendix vii Example of retest plan III form](#)
[Appendix Viii Example of final reporting for atypical/OOS result investigation form](#)
[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 01

[Table 1.1 Regulatory sections of Part 211—current good manufacturing practice for finished pharmaceuticals](#)

[Table 1.2 Regulatory sections of Part 820—quality system regulation](#)

[Table 1.3 Regulatory sections of Part 600—biological products: general](#)

[Table 1.4 Regulatory sections of Part 601—biologic license application](#)

[Table 1.5 Regulatory sections of Part 610—general biological product standards](#)

[Table 1.6 Summary of application type and designated regulating center](#)

[Table 1.7 Compliance programs of CBER](#)

[Table 1.8 Compliance program in BIMO](#)

[Table 1.9 Compliance program in CDRH](#)

[Table 1.10 CDER compliance program](#)

Chapter 02

[Table 2.1 Content of a typical target product profile for an immediate-release tablet](#)

[Table 2.2 Typical target product profile: project plan and milestones for an immediate-release tablet](#)

[Table 2.3 Typical target product profile: clinical targets](#)

[Table 2.4 Typical target product profile: drug substance characteristics for an immediate-release tablet](#)

[Table 2.5 Typical target product profile: drug product characteristics of an immediate-release tablet](#)

[Table 2.6 Typical target product profile: drug substance specifications of an immediate-release tablet](#)

[Table 2.7 Typical target product profile: drug product specifications of an immediate-release tablet](#)

[Table 2.8 Typical target product profile: formulation composition of an immediate-release tablet](#)

[Table 2.9 Example of a checklist to select excipients for an immediate-release tablet](#)

[Table 2.10 Typical target product profile: manufacturing process of an immediate-release tablet](#)

Chapter 03

[Table 3.1 Common polymers used in amorphous solid dispersions and their glass transition temperature](#)

Chapter 04

[Table 4.1 Classes of medical instruments in the United States, Europe, and Canada](#)

[Table 4.2 Summary of the main routes of administration that require a medical device to facilitate drug delivery](#)

[Table 4.3 Examples of inhalers for topical delivery to the lung](#)

[Table 4.4 Examples of inhalers for systemic delivery via the lung](#)

[Table 4.5 Examples of si dosage forms](#)

[Table 4.6 ATMP types and key characteristics^a](#)

Chapter 05

[Table 5.1 ISO 10993 recommended testing and evaluation](#)

[Table 5.2 Summary of bone growth factor technologies commercially available and in development](#)

Chapter 07

[Table 7.1 Human islet transplantation studies currently recruiting](#)

Chapter 08

[Table 8.1 Cytotoxic T-cell \(CTL\) studies conducted by a commercial sponsor](#)

[Table 8.2 TCR gene therapy studies conducted by a commercial sponsor](#)

[Table 8.3 Car gene therapy studies conducted by an academic sponsor](#)

[Table 8.4 NK cell studies conducted by a commercial sponsor](#)

[Table 8.5 Antigen-presenting cell types and characteristics](#)

[Table 8.6 DC-based vaccine trials conducted by a commercial sponsor](#)

Chapter 09

[Table 9.1 Key chronological events of stem cell development](#)

[Table 9.2 Major ongoing randomized stem cell trials conducted by a commercial sponsor](#)

Chapter 10

[Table 10.1 Example specification of ABC DS](#)

[Table 10.2 Example specification of ABC capsule](#)

[Table 10.3 Example changes during development of XYZ capsule](#)

[Table 10.4 Test methods used in DSs](#)

[Table 10.5 Test methods used in DPs](#)

[Table 10.6 Example stability protocol template for ABC capsules](#)

[Table 10.6.1 Example table summary of ABC capsule formulations](#)

[Table 10.6.2 Pull points for ABC capsules](#)

[Table 10.6.3 Testing guidelines](#)

[Table 10.7 Usual storage conditions used in stability studies](#)

Chapter 11

[Table 11.1 LC-MS applications in different stages of drug development](#)

[Table 11.2 Common liquid chromatographic systems, ionization interfaces, and mass detectors for LC-MS and LC-MS/MS systems](#)

[Table 11.3 Performance of mass detectors](#)

Chapter 12

[Table 12.1 Apparatus typically used for special dosage forms](#)

[Table 12.2 Simple media used in dissolution testing](#)

[Table 12.3 SGF composition](#)

[Table 12.4 FaSSIF composition](#)

[Table 12.5 FeSSIF composition](#)

[Table 12.6 Simulated colonic fluid 1 \(SCoF1\)](#)

[Table 12.7 Simulated colonic fluid 2 \(SCoF2\)](#)

[Table 12.8 Properties of FaSSCoF and FeSSCoF](#)

[Table 12.9 Parameters used in IVIVC corresponding to the level](#)

Chapter 13

[Table 13.1 ICH Harmonization Activities](#)

List of Illustrations

Chapter 02

[Figure 2.1 High-level product development stages/phases, activities, and milestones.](#)

[Figure 2.2 Elements defining a pharmaceutical dosage form design.](#)

[Figure 2.3 Relationship between clinical, solid-state, and formulation development.](#)

[Figure 2.4 Example of a decision tree to develop drug substance specifications for an immediate-release tablet.](#)

[Figure 2.5 Process development steps for a typical immediate-release tablet.](#)

[Figure 2.6 Decision tree of selecting a manufacturing process for an immediately-release tablet.](#)

[Figure 2.7 Risk assessment and experimental design of a wet granulation process for a tablet formulation using a fishbone diagram.](#)

[Figure 2.8 Process optimization of MCC and lactose granulates by statistical design of experiment.](#)

Chapter 03

[Figure 3.1 Typical approach of formulation screening to improve the bioavailability of poorly soluble compounds.](#)

[Figure 3.2 An example of an uncertain path to improve bioavailability. Reproduced from Ref. 2, with permission of Patheon, Inc.](#)

[Figure 3.3 Biopharmaceutical classification system.](#)

[Figure 3.4 From dosing to systematic circulation—factors affecting bioavailability of poorly soluble compounds.](#)

[Figure 3.5 Summary of bioavailability enhancement technologies available in both development and commercial settings. Courtesy of Patheon Inc., with modification.](#)

[Figure 3.6 Particle engineering of drug candidate for formulation development.](#)

[Figure 3.7 An example of parallel technology screening program using a decision tree approach for human formulation. .](#)

[Figure 3.8 Excipient screening for solid dispersions using DSC—*in situ* formation and analysis of](#)

griseofulvin and PVP K 30 (10% (w/w)) solid dispersion. Courtesy of Patheon Inc.

Figure 3.9 Optical microscopy of (a) crystalline—PEG 3350 and (b) amorphous—SoluPlus® materials under cross-polarized light. Courtesy of Patheon Inc.

Figure 3.10 Decision tree for selection of technology and formulation to improve the bioavailability of poorly soluble drugs.

Chapter 04

Figure 4.1 Verification and validation of medical devices.

Figure 4.2 EpiPen® injector device. Reproduced with permission of Mylan Specialty L.P.

Figure 4.3 Turbuhaler® inhaler. Reproduction of Pulmicort® device provided courtesy of AstraZeneca Canada Inc.

Figure 4.4 Afrezza® inhaler (palm size). Reproduction of Afrezza device provided courtesy of MannKind Corporation.

Chapter 05

Figure 5.1 Systemic detection of a growth factor injection versus local retention of the growth factor by a carrier.

Figure 5.2 Local retention of a growth factor by different carriers that utilize both absorption (CaP granules, composite material, and collagen) and incorporation (both CaP cements).

Figure 5.3 An SEM image of a fibrous collagen scaffold with interconnected porosity.

Figure 5.4 Collagen (a), a natural polymer; biphasic calcium phosphate (b), a synthetic ceramic; and

[collagen and ceramic scaffold \(c\), a composite.](#)

Chapter 06

[Figure 6.1 Healthy volunteer insulin and glucose profiles. Reproduced from Ref. 2, with permission of McStroher, Creative Commons.](#)

[Figure 6.2 Glass syringes. © Bill Van Antwerp.](#)

[Figure 6.3 DCCT data. © Bill Van Antwerp.](#)

[Figure 6.4 Backpack pump. © Bill Van Antwerp.](#)

[Figure 6.5 Early insulin pump. Courtesy of Squidonius, Creative Commons.](#)

[Figure 6.6 Early insulin pump AutoSyringe. © Bill Van Antwerp.](#)

Chapter 08

[Figure 8.1 Structure of a typical CAR. 4-1BB or OX-40, costimulatory molecules belonging to the TNF/nerve growth factor super family of receptors; CD28, cluster of differentiation 28, provides costimulatory signal; CD3 \$\zeta\$, cluster of differentiation 3 \$\zeta\$, generates an activation signal in T lymphocytes; CD8, cluster of differentiation 8, a transmembrane glycoprotein that serves as a coreceptor for the TCR; C_H, constant region of heavy chain; C_L, constant region of light chain; scFv, single-chain variable fragment; V_H, variable region of heavy chain; V_L, variable region of light chain.](#)

Chapter 10

[Figure 10.1 Drug development cycle.](#)

Chapter 11

[Figure 11.1 Schematic of an ESI interface.](#)

[Figure 11.2 Schematic of an APCI interface.](#)

[Figure 11.3 Schematic diagram showing the different operation ranges for APCI and ESI in terms of relative polarity, mass range, and target analytes.](#)

[Figure 11.4 Schematic of the configuration of a quadrupole mass analyzer.](#)

[Figure 11.5 Schematic of the configuration of the electrodes in a 3D IT mass analyzer.](#)

[Figure 11.6 Schematic diagram showing the basic operation principle of TOF mass analyzer.](#)

[Figure 11.7 Scan mode for LC-MS/MS applications.](#)

[Figure 11.8 Mometasone furoate and its related impurities.](#)

[Figure 11.9 \(a\) MS spectrum of nonlabeled melamine. \(b\) MS spectrum of nonlabeled and labeled melamine. \(c\) Extracted ion chromatograms of the transitions of nonlabeled and labeled melamine and a calibration curve constructed based on the area ratio of ion nonlabeled and labeled melamine ion fragments.](#)

[Figure 11.10 Work for shotgun proteomics.](#)

[Figure 11.11 Chemical structure of the iTRAQ reagents and the stable isotope combinations.](#)

[Figure 11.12 Workflow of an iTRAQ experiment for protein quantitation.](#)

Chapter 12

[Figure 12.1 Factors that might impact drug dissolution. Reproduced from Ref. 7](#)

[Figure 12.2 Apparatus 1 and 2 dissolution test.](#)

Figure 12.3 Franz cells as described in *Pharmacopeial Forum*. Reproduced from *Pharmacopeial Forum*, May-June 2009, with permission of the US Pharmacopeial Convention

Figure 12.4 Comparison of the solubility of montelukast (a) and glyburide (b) between high and low purity grades of taurocholate and lecithin.

Figure 12.5 (a) pH, surface tension, protein content, and total carbohydrate concentration of FaSSCoF and FeSSCoF compared to human colonic fluids. (b) Osmolarity, total bile, long-chain fatty acids, phosphatidylcholine, and cholesterol of FaSSCoF and FeSSCoF compared to human colonic fluids. Reproduced from Refs. 41 and 50.

Figure 12.6 A schematic of a PBPK model. Adopted simulation plus workshop. Reproduced from Ref. 68, with permission of Simulations Plus, Inc.

Figure 12.7 Biopharmaceutical parameters used to assess IVIVCs. If dissolution is faster than absorption, then the process is permeability controlled. If dissolution controls drug absorption, the dissolution testing might be a surrogate for *in vivo* dissolution. Reproduced from Ref. 7.

Figure 12.8 Dissolution specifications for Class I/III (a) and dissolution specifications for Class II/IV bioequivalence (BE) is expected in case (a) if a minimum required dissolution is achieved, in case (b) a minimum and maximum dissolution is required for BE.

Figure 12.9 Level B correlation between the *in vitro* MDT and *in vivo* MRT. Reproduced from Ref. 80, with permission of Springer Science and Business Media.

Figure 12.10 Left: mean *in vitro* dissolution data (a) and *in vivo* plasma concentration data (b) for metformin. Right: level C IVIVC for metformin. Mean observed AUC as a function of *in vitro* dissolution at 0.5, 2, and 4 h (a). AUC plotted versus the *in vitro* MDT (b). Reproduced from Ref. 62, with permission of Wiley-Liss, Inc. and the American Pharmaceutical Association.

Figure 12.11 pH-dependent calculated Do for 80 mg gliclazide dose. Dotted lines represent the critical Do for GLK (conservative upper limit of $Do = 1$ and the calculated value of $Do = 14.5$). Reproduced from Ref. 82, with permission of Springer Science and Business Media

Figure 12.12 Dissolution of montelukast sodium in different dissolution media using USP apparatus 2 and a flow-through cell. The profiles were used in GastroPlus to simulate the *in vivo* performance. Reproduced from Ref. 45, with permission of Elsevier.

Therapeutic Delivery Solutions

Edited by

Chung Chow Chan

CCC Consulting

Mississauga, Ontario, Canada

Kwok Chow

Covar, Inc.

Mississauga, Ontario, Canada

Bill McKay

Medtronic, Inc.

Memphis, TN, USA

Michelle Fung

Gordon and Leslie Diamond Health Care Centre

University of British Columbia

Vancouver, British Columbia, Canada

WILEY

Copyright © 2014 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey

Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permissions>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Therapeutic delivery solutions / edited by Chung Chow Chan, Kwok Chow, Bill McKay, Michelle Fung.

p. ; cm.

Includes index.

ISBN 978-1-118-11126-0 (cloth)

I. Chan, Chung Chow, editor. II. Chow, Kwok, 1956- editor. III. McKay, Bill, 1956- editor.

IV. Fung, Michelle, editor.

[DNLM: 1. Drug Delivery Systems-United States. 2. Cell- and Tissue-Based Therapy-methods-United States. QV 785]

RS199.5
615'.6-dc23
2014007293

Preface

The technologies for the administration of therapeutic agents have been traditionally led by the pharmaceutical industry that develops drug molecules (both small and large molecules) in various dosage forms. The medical device industry has also evolved to apply its technologies to deliver drugs to various target sites.

Cellular therapy is now rapidly emerging as a new therapeutic solution platform, analogous to dosage form design and device development, in the last few decades. Under the Executive Order 13505 of March 9, 2009, in the United States, President Obama's Administration is committed to supporting and conducting ethically responsible, scientifically worthy human stem cell research, including human embryonic stem cell research. "National Institutes of Health Guidelines for Human Stem Cell Research" (Guidelines), effective July 7, 2009, applies to research using human embryonic stem cells and certain uses of human-induced pluripotent stem cells that have the potential to improve our understanding of human biology and aid in the discovery of new ways to prevent and treat illness. Researches in cellular therapy, for example, stem cells, have had very promising results as therapeutic solutions to diseased states and organ transplants.

This textbook provides a convergent link between traditional dosage form design, medical device development, and cellular therapeutics. It attempts to bring these three platforms of therapeutic delivery solution development together in one place to show the potential idiosyncrasies and common and dissimilar challenges that each platform faces to provide the best therapeutic delivery solution to the patient. Contemporary scientific and

medical information as well as the newly emerging regulatory scientific information are discussed. This textbook will provide development scientists and medical professionals more options to develop a therapeutic agent to its fullest potential and create better and more creative therapeutic solutions.

The content of the book is grouped into five sections. [Section 1](#) (consisting of [Chapter 1](#)) introduces the requirements and issues encountered in regulatory submissions in the pharmaceutical, cellular/gene products, and medical device industries. [Section 2](#) (consisting of [Chapters 2](#) and [3](#)) explains in detail the traditional pharmaceutical drug therapy development. [Section 3](#) (consisting of [Chapters 4-6](#)) provides an overview, current trends, and strategies of special medical device development. [Section 4](#) (consisting of [Chapters 7-9](#)) introduces the reader to the latest advances and innovations in cellular and stem cell therapeutic delivery. [Section 5](#) (consisting of [Chapters 10-14](#)) provides information on the analytical support needed for the research and development in [Sections 2-4](#).

[Chapter 1](#) provides an overview of the current regulatory requirements for the development of the three platforms of therapeutic solution and new FDA initiatives to ensure that innovative products reach the patients who need them and when they need them.

An overview of the approach and strategies for development of immediate release tablets after a drug candidate is selected is provided in [Chapter 2](#). [Chapter 3](#) discusses the strategies (with examples) for the development of low aqueous solubility drug products.

[Chapter 4](#) starts with an overview, key trends, and drivers for drug delivery medical devices. [Chapter 5](#) focuses on the local growth factor delivery to address metabolic bone

disorders. “From glass syringes to feedback-controlled patch pumps”, [Chapter 6](#) discusses the amazing accomplishment for the pharmaceutical and medical device industries with the insulin pump to continuously deliver precise amounts of insulin 24 h a day.

Cell-based biologic therapies have a long history. Simple blood transfusions and tissue transplants are commonly utilized in medical practice. [Chapter 7](#) reviews the history of islet transplantation, procedural issues, current outcomes, and future directions. [Chapter 8](#) provides an overview of the latest developments of cell-based biologic therapies and discusses the future outlook for these novel treatment modalities, for example, cancer, infection, and autoimmune disorders. [Chapter 9](#) reviews the history of stem cell research and development, sources of various stem cells (e.g., neonatal, adult, reprogrammed), technical and regulatory issues of stem cell therapy, and the prospect of industrialization of stem cell technology into future medical therapy.

[Chapters 10](#) to [14](#) provide the analytical support needed in the development of the three platforms of therapeutic solution delivery. [Chapter 10](#) summarizes the specifications setting and stability studies requirements for development work. [Chapter 11](#) shows how LC-MS techniques have been used in all stages of the drug development process including discovery, preclinical, clinical, and manufacturing. [Chapter 12](#) discusses the importance of biorelevant methods and how to achieve them. [Chapter 13](#) provides information and importance of ICH guidelines for development and global harmonization. In the development of therapeutic solution, there will be situations when out of specification (OOS) or aberrant data are obtained. [Chapter 14](#) looks at how the use of sound scientific judgment and good documentation can lead to a successful OOS/atypical

result investigation in a case study according to current guidance.

CCC Consulting

Covar Inc.

Medtronic Inc.

University of British Columbia

Chung Chow Chan, PhD

Kwok Chow, PhD

Bill McKay, ME

Michelle Fung, MD

Contributors

May Almukainzi, PhD, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada; Faculty of Pharmacy, Princess Nora Bint AbdulRahman University, Riyadh, Saudi Arabia

Ziliang Ao, MD, MSc, Ike Barber Human Islet Transplant Laboratory Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

James Blakemore, PhD, Cambridge Consultants Ltd., Science Park, Cambridge, UK

Nádia Araci Bou-Chacra, PhD, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil

Debra L. Bowen, MD, FCAAI, Pharma Science Consulting, Inc., Milford, NH, USA

Chung Chow Chan, PhD, CCC Consulting, Mississauga, Ontario, Canada

Kwok Chow, PhD, Covar, Inc., Mississauga, Ontario, Canada

Jared Diegmüller, MS, Medtronic Spinal and Biologics, Memphis, TN, USA

Man C. Fung, MD, MBA, MHCM, FACP, Janssen Pharmaceutical R&D (JNJ), Janssen Oncology, Raritan, NJ, USA

Michelle Fung, BSc, MD, MHSc, Department of Medicine, Faculty of Medicine, University of British Columbia,

Vancouver, British Columbia, Canada

Sultan Ghani, BSc, BPharm, MS, Quality Management & Regulatory Affairs (QMRA), Getz Pharma Pvt. Limited, Karachi, Pakistan

Stephen G.F. Ho, MD, FRCPC, Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Klaudyne Hong, PhD, Temasek Bioscience Partners, NY, USA

James D. Johnson, PhD, Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Paul Keown, MD, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Herman Lam, PhD, Wild Crane Horizon, Scarborough, Ontario, Canada

Raimar Löbenberg, PhD, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

Bill McKay, ME, Medtronic Spinal and Biologics, Memphis, TN, USA

Mark Meloche, MD, Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Graydon Meneilly, MD, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Breay W. Paty, MD, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Steven Peckham, PhD, Medtronic Spinal and Biologics,
Memphis, TN, USA

R. Jean Shapiro, MD, Department of Medicine, Faculty of
Medicine, University of British Columbia, Vancouver,
British Columbia, Canada

Iain Simpson, PhD, Cambridge Consultants Ltd., Science
Park, Cambridge, UK

David Thompson, MD, Department of Medicine, Faculty
of Medicine, University of British Columbia, Vancouver,
British Columbia, Canada

Yu-Hong Tse, PhD, YH & MJ Consulting, Brampton,
Ontario, Canada

Bill Van Antwerp, Zyomed Corp., Valencia, CA, USA

Bruce Vechere, PhD, Pathology & Laboratory Medicine
and Surgery, Faculty of Medicine, University of British
Columbia, Vancouver, British Columbia, Canada

Roderick B. Walker, Faculty of Pharmacy, Rhodes
University, Grahamstown, South Africa

Garth Warnock, MD, MSc, Department of Surgery,
Faculty of Medicine, University of British Columbia,
Vancouver, British Columbia, Canada

Acknowledgment

We would like to thank all the authors and contributors who are leading scientists and physicians in the respective areas for their contributions to the chapters in this book.

Section 1
Requirements and
Issues encountered in Regulatory
Submissions in the Pharmaceutical,
Cell Therapy and Medical Device
Industries